查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853418

先进治疗药物CDMO市场按产品类型、服务类型、治疗领域、应用和最终用户划分 - 全球预测（2025-2032年）

Advanced Therapy Medicinal Products CDMO Market by Product Type, Service Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，先进疗法 CDMO 市场将成长至 284.6 亿美元，复合年增长率为 17.71%。

关键市场统计数据
基准年2024年 77.1亿美元
预计年份：2025年 89.7亿美元
预测年份 2032 284.6亿美元
复合年增长率（%） 17.71%

本文概述了技术成熟度和业务需求如何再形成CDMO在细胞、基因和组织工程疗法领域中的角色，并提出了一个简洁的策略框架。

先进治疗产品（ATMP）合约开发与受託製造厂商（CDMO）产业处于科学创新与工业规模生物加工的交会点。细胞疗法、基因疗法和组织工程的快速发展正在改变服务供应商的研发路径和营运预期，并引发分析、製程开发、生产和监管等职能能力的重组。随着申办者从发现研究推进到临床和商业化供应，他们越来越需要能够将深厚的生物加工专业知识与监管策略、品质系统和可扩展的生产平台相结合的合作伙伴。

本执行摘要总结了目前影响供应商选择、投资重点和竞争差异化的动态因素。它重点阐述了技术成熟度、监管演变和供应链现状如何推动合约研发生产机构（CDMO）拓展服务范围并提升专业化水准。本书将科学趋势与商业需求结合，为领导者提供清晰的观点，帮助他们明确资源部署方向、优先弥补哪些能力缺口，以及如何调整组织架构以支援小分子生技药品和复杂工程化药物的研发。本书旨在帮助决策者将技术洞见转化为切实可行的策略行动，从而在不影响品质或合规性的前提下，降低专案风险并加快研发进程。

科学创新、监管预期和商业化压力如何推动CDMO拓展自身能力并建立更深的伙伴关係关係

在科学突破和商业性前景的共同推动下，ATMP（先进治疗药物）领域正发生变革性转变，迫使CDMO（合约研发生产机构）超越传统的生产服务模式。载体设计、细胞工程和支架技术的进步增加了製程的复杂性，同时也为实现以往难以企及的持久临床疗效铺平了道路。因此，CDMO必须平衡对专用无尘室架构和一次性技术的投资，以及对细胞和载体分析的投资，以实现稳健的表征和可比性。

同时，支付方和监管机构越来越重视长期证据的产生和供应的稳定性，这促使申办方选择能够支持其从早期临床开发到商业化全生命週期策略的合作伙伴。这种趋势推动了更深层的策略联盟，CDMO参与平台开发、监管申报支援和上市后生产保障。这种转变强调了灵活的能力、数据的完整性和跨职能的计划管治，成功的供应商展现了降低研发风险、优化成本和缩短临床试验时间的能力。

因应2025年关税政策带来的供应链和製造地策略的调整，以维持业务连续性和成本效益。

2025年新关税的实施为原材料采购、专用一次性零件采购和跨境製造服务采购带来了新的成本和复杂性，相关人员必须应对这些挑战。关税主导的成本压力迫使赞助商和服务供应商重新评估其供应链的韧性，实现供应商多元化，并在可行的情况下加快在地化策略。在某些情况下，製造商正在调整采购计划，优先选择来源透明且关税合规记录良好的供应商，从而减少海关延误和意外成本转嫁。

此外，关税环境正在影响临床和商业供应的生产能力选址的策略决策。申办方越来越倾向于权衡集中式高产能生产基地和区域分散式生产模式之间的利弊，后者可以减轻关税的影响并缩短物流路径。 CDMO（合约研发生产机构）则透过加强海关专业知识、建立稳健的库存缓衝以及製定成本分配框架来应对这一挑战，从而在保持供应可靠性的同时，维持专案的经济效益。

一种以细分市场主导、细緻入微的视角，展现了产品模式、服务范围、治疗领域、应用阶段和最终用户画像如何定义CDMO的差异化价值提案。

市场区隔洞察揭示了不同的需求驱动因素和产能需求，从而指南产品组合开发和市场推广策略。依产品类型划分，可分为细胞疗法、基因疗法和组织工程产品。在细胞疗法领域，需求可细分为非干细胞疗法和干细胞疗法；而在基因疗法领域，需求则可细分为生殖系基因疗法和体细胞基因疗法。这些治疗方式的差异会影响供应商必须提供的检测类型和规模、滴度测定以及产品放行检测，以避免临床进展风险。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • CDMO的商业化同种异体细胞疗法生产能力迅速扩张
  • 整合数位化过程监控和分析，以提高ATMP批次一致性
  • 监管协调工作旨在简化先进治疗方法的全球核准
  • 与生物技术创新企业建立策略性CDMO伙伴关係，以实现产量产量病毒载体的生产。
  • 引入封闭式自动化生产线以降低ATMP污染风险
  • 投资建造灵活的多产品生产设施，以适应各种基因​​和细胞疗法。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的先进治疗药物CDMO市场

  • 细胞治疗产品
    • 非干细胞疗法
    • 干细胞疗法
  • 基因治疗产品
    • 生殖细胞疗法
    • 体细胞基因治疗
  • 组织工程产品

9. 按服务类型分類的先进治疗药物CDMO市场

  • 分析测试和品管
  • 製造服务
  • 流程开发服务
  • 监管和合规支持

第十章：按治疗领域分類的先进治疗药物CDMO市场

  • 心臟病学
  • 皮肤科
  • 血液学
  • 神经病学
  • 肿瘤学

第十一章：按应用领域分類的先进治疗药物CDMO市场

  • 临床阶段
  • 商业阶段

第十二章：按最终用户分類的先进治疗药物CDMO市场

  • 学术研究机构
  • 生物製药公司

第十三章：按地区分類的先进治疗药物CDMO市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：按集团分類的先进治疗药物CDMO市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：各国先进治疗药物CDMO市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abzena
    • Advanced Therapies, LLC
    • AGC Inc.
    • Aldevron
    • Almac Group
    • Bio Elpida by Polyplus
    • BlueReg
    • Catalent Inc.
    • CELONIC Group
    • CGT Catapult
    • Charles River Laboratories International, Inc.
    • Coriolis Pharma Research GmbH
    • Curia Global, Inc.
    • Eurofins Scientific SE
    • FUJIFILM Diosynth Biotechnologies
    • Lonza Group
    • Minaris Regenerative Medicine
    • Oxford Biomedica PLC
    • Patheon by Thermo Fisher Scientific Inc.
    • Recipharm AB
    • Rentschler Biopharma SE
    • REPROCELL Inc.
    • RoslinCT
    • Samsung Biologics
    • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market is projected to grow by USD 28.46 billion at a CAGR of 17.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.71 billion
Estimated Year [2025] USD 8.97 billion
Forecast Year [2032] USD 28.46 billion
CAGR (%) 17.71%

A concise strategic framing of how technological maturation and operational demands are reshaping CDMO roles for cell, gene, and tissue engineered therapeutics

The advanced therapy medicinal products (ATMP) contract development and manufacturing organization (CDMO) sector sits at the intersection of scientific innovation and industrial-scale bioprocessing. Rapid advances in cell therapy, gene therapy, and tissue engineering are shifting development pathways and operational expectations for service providers, triggering a reframing of capabilities across analytical, process development, manufacturing, and regulatory functions. As sponsors progress from exploratory research to clinical and commercial supply, they increasingly require partners who can integrate deep bioprocess expertise with regulatory strategy, quality systems, and scalable manufacturing platforms.

This executive summary synthesizes current dynamics shaping provider selection, investment priorities, and competitive differentiation. It emphasizes how technological maturation, regulatory evolution, and supply chain realities are driving CDMOs to expand service breadth while enhancing specialization. The narrative connects scientific trends to operational imperatives, offering leaders a clear perspective on where to align resources, which capability gaps to prioritize closing, and how to position organizations to support both small molecule-free biologics and complex engineered modalities. The intent is to help decision-makers convert technical insights into practical strategic actions that reduce program risk and accelerate timelines without compromising quality or compliance.

How converging scientific innovation, regulatory expectations, and commercialization pressures are compelling CDMOs to expand capabilities and form deeper partnerships

Transformative shifts in the ATMP landscape are driven by the confluence of scientific breakthroughs and commercial expectations, pressing CDMOs to evolve beyond traditional manufacturing service models. Advances in vector design, cell engineering, and scaffold technologies are increasing process complexity while simultaneously opening routes to durable clinical responses that were previously unattainable. As a result, CDMOs must balance investments in specialized cleanroom architectures and single-use technologies with investments in cell and vector analytics that enable robust characterization and comparability.

Concurrently, payers and regulators are emphasizing long-term evidence generation and supply consistency, which motivates sponsors to select partners capable of supporting lifecycle strategies from early clinical development through commercialization. This dynamic is fostering deeper strategic alliances where CDMOs participate in platform development, regulatory filing support, and post-market manufacturing assurance. The shift places a premium on flexible capacity, data integrity, and cross-functional project governance, with successful providers demonstrating an ability to de-risk development pathways while optimizing cost and time to clinic.

Navigating the 2025 tariff-driven recalibration of supply chains and manufacturing location strategies to maintain continuity and cost-effectiveness

The imposition of new tariff measures in 2025 has introduced an additional cost and complexity vector that stakeholders must navigate in sourcing raw materials, specialized single-use components, and cross-border manufacturing services. Tariff-driven cost pressures have prompted sponsors and service providers to reassess supply chain resilience, diversifying supplier bases and accelerating localization strategies where feasible. In some cases, manufacturers are reconfiguring procurement plans to prioritize vendors with transparent origin and tariff compliance histories to reduce customs delays and unexpected cost pass-throughs.

Moreover, the tariff environment has influenced strategic decisions around where to locate manufacturing capacity for clinical and commercial supply. Sponsors are increasingly weighing the trade-offs between centralized high-capacity sites versus distributed regional manufacturing models that can mitigate tariff exposure and shorten logistical pathways. Regulatory dossiers and quality systems must be adjusted to reflect multi-jurisdictional production plans, and CDMOs are responding by enhancing customs expertise, implementing robust inventory buffers, and developing cost-allocation frameworks that preserve program economics while maintaining supply reliability.

A nuanced segmentation-driven lens showing how product modalities, service scopes, therapeutic areas, application stages, and end-user profiles define differentiated CDMO value propositions

Segmentation insights reveal differentiated demand drivers and capability requirements that should guide portfolio development and go-to-market strategies. Based on Product Type, the landscape includes Cell Therapy Products, Gene Therapy Products, and Tissue Engineered Products; within cell therapies, demand separates between Non-stem Cell Therapy and Stem Cell Therapy, while gene therapy distinctions arise between Germline Therapy and Somatic Gene Therapy, each pathway carrying unique manufacturing and regulatory considerations. These modality distinctions influence the type and scale of analytics, potency assays, and release testing that providers must offer to de-risk clinical progression.

Based on Service Type, service expectations encompass Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, and Regulatory & Compliance Support, and the most competitive providers integrate these capabilities to provide seamless technology transfer and comparability assessments. Based on Therapeutic Area, the sector spans Cardiology, Dermatology, Hematology, Neurology, and Oncology, with oncology and hematology programs frequently demanding accelerated timelines, complex release criteria, and higher regulatory scrutiny. Based on Application, differentiation between Clinical Stage and Commercial Stage use cases requires flexibility in batch size, facility qualification, and supply chain robustness. Based on End-User, the market engages both Academic & Research Institutes and Biopharmaceutical Companies, which present divergent needs around cost sensitivity, regulatory sophistication, and expectations for long-term manufacturing partnerships.

Taken together, these segmentation axes show that successful service providers must architect modular offerings that can be configured to meet modality-specific analytical demands, therapeutic area nuances, and the distinct operational rhythms of early-stage researchers versus commercial sponsors. This segmentation-informed approach enables targeted investment in platform technologies and quality infrastructures that align with customer priorities and regulatory pathways.

How regional manufacturing ecosystems and regulatory landscapes are influencing sourcing choices and the geographical distribution of advanced therapy production capacity

Regional dynamics are reshaping where sponsors elect to conduct development and secure commercial supply, with geographic strengths and constraints influencing provider specialization and client engagement models. In the Americas, investment into flexible manufacturing and advanced analytics is creating hubs that emphasize speed to clinic for early-phase programs and support for scale-up activities. Talent concentration and established regulatory pathways make the region attractive for complex modality development, but high operational costs incentivize hybrid models that combine domestic capacity with offshore manufacturing for non-core processes.

In Europe, Middle East & Africa, regulatory harmonization efforts and incentives in several jurisdictions support a diverse provider ecosystem that blends academic spinouts with industrial-scale CDMOs. This regional tapestry fosters collaborative innovation but also requires close attention to cross-border regulatory alignment and localized compliance requirements. In Asia-Pacific, rapid capacity expansion, competitive manufacturing cost structures, and growing scientific talent pools are driving an increasing share of clinical and commercial manufacturing activities, though sponsors must carefully evaluate quality standards and supply chain traceability when engaging new partners.

These regional distinctions encourage sponsors to adopt multi-regional sourcing strategies that balance speed, cost, and regulatory security. Providers that can demonstrate validated processes across jurisdictions, harmonized quality systems, and robust logistics will be better positioned to capture cross-border demand and to support clients pursuing global clinical development and commercialization pathways.

An assessment of provider strategies showing how capability consolidation, targeted specialization, and strategic partnerships are shaping competitive advantage in CDMO services

Company-level dynamics are centered on capability integration, platform scalability, and strategic partnerships that bridge scientific development with commercial readiness. Leading providers are investing in end-to-end capability stacks, combining rigorous analytical testing, advanced process development, and regulatory support to present cohesive value propositions for complex cell and gene therapy programs. These investments often pair with targeted alliances, technology licenses, or joint development agreements that accelerate access to specialized vectors, cell expansion platforms, and potency assay technologies.

At the same time, the competitive field includes specialist providers that maintain high-value niches, such as vector manufacturing or bespoke tissue engineering services, which can be highly attractive to sponsors seeking domain-specific expertise. Mergers and acquisitions continue to be a strategic lever for scaling capacity and absorbing specialized know-how, while organic investments in single-use infrastructure and digital quality systems enhance operational responsiveness. For sponsors, the optimal partner selection balances an assessment of technical fit, track record in regulatory submissions, and the provider's governance model for risk sharing and traceability during technology transfers.

Actionable strategies for leaders to enhance resilience, scale capabilities, and forge deeper, risk-aligned partnerships across the advanced therapy CDMO continuum

Industry leaders should adopt a proactive agenda that balances near-term operational resilience with longer-term capability building. Immediate priorities include strengthening supply chain transparency for critical raw materials and single-use consumables, formalizing multi-sourcing strategies to mitigate tariff and logistics exposure, and implementing robust inventory and batch-tracking mechanisms that align with multi-jurisdictional regulatory expectations. Parallel investments in advanced analytics and potency assays will improve comparability and batch release confidence, reducing downstream regulatory friction.

Over the medium term, organizations should prioritize modular facility design and platform standardization to enable rapid scaling from clinical to commercial manufacture. Cultivating strategic partnerships with vector specialists, academic translation centers, and technology licensors can accelerate time-to-clinic while distributing development risk. Leadership should also invest in workforce development programs that build cross-disciplinary expertise in process development, regulatory affairs, and quality systems. Finally, aligning commercial engagement models to offer outcome-linked milestones or shared risk arrangements can differentiate providers and foster deeper, longer-term sponsor relationships that support streamlined development and market entry.

A rigorous mixed-method research approach integrating primary interviews, technical literature review, and capability mapping to deliver validated insights for decision-makers

The analysis underpinning this report synthesizes primary and secondary inputs to produce an evidence-based view of provider capabilities, market dynamics, and operational trends. Primary research included structured interviews with senior leaders across development-stage sponsors, manufacturing executives, process scientists, and regulatory specialists to capture first-hand perspectives on operational priorities and partnership criteria. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and technical white papers to triangulate technological and compliance trends relevant to advanced modalities.

Analytical methods combined qualitative thematic analysis of interview transcripts with capability mapping and scenario-based risk assessment to evaluate how tariff changes, regional dynamics, and modality complexity influence sourcing and manufacturing strategies. Comparative provider profiling emphasized observable metrics such as facility type, service breadth, historical regulatory interactions, and documented platform technologies. Where possible, the methodology prioritized verifiable, primary-source evidence and cross-validation to ensure findings are robust and actionable for decision-makers seeking to align manufacturing strategies with clinical and commercial objectives.

Strategic imperatives for aligning scientific platforms, manufacturing readiness, and regulatory foresight to support the full lifecycle of advanced therapy programs

Advanced therapy CDMO strategy is increasingly about orchestrating scientific excellence, manufacturing rigor, and regulatory foresight into cohesive partnerships that reduce program risk and accelerate patient access. The combined pressures of technological complexity, tariff dynamics, and regional manufacturing evolution make it imperative for both sponsors and providers to adopt flexible, platform-based approaches and to deepen collaborations that bridge bench science to scalable production. By aligning investments in analytics, modular facilities, and compliance infrastructure with targeted therapeutic area expertise, stakeholders can improve predictability across development stages.

Decision-makers who prioritize transparent supply chains, validated multi-regional capabilities, and shared-risk commercial models will be better positioned to navigate uncertainty while capturing the value of advanced modalities. The path forward is one of selective specialization complemented by interoperable platforms, enabling providers to support the full lifecycle of ATMP programs while maintaining quality and regulatory alignment. This strategic orientation will determine which organizations can reliably serve the complex needs of next-generation therapeutics and sustain long-term partnerships with sponsors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of allogeneic cell therapy commercial manufacturing capacity at CDMOs
  • 5.2. Integration of digital process monitoring and analytics to improve ATMP batch consistency
  • 5.3. Regulatory harmonization efforts enabling streamlined global approval of advanced therapies
  • 5.4. Strategic CDMO partnerships with biotech innovators for high-yield viral vector production
  • 5.5. Deployment of closed, automated manufacturing lines to reduce contamination risk in ATMPs
  • 5.6. Investment in flexible multi-product facilities to accommodate diverse gene and cell therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Therapy Medicinal Products CDMO Market, by Product Type

  • 8.1. Cell Therapy Products
    • 8.1.1. Non-stem Cell Therapy
    • 8.1.2. Stem Cell Therapy
  • 8.2. Gene Therapy Products
    • 8.2.1. Germline Therapy
    • 8.2.2. Somatic Gene Therapy
  • 8.3. Tissue Engineered Products

9. Advanced Therapy Medicinal Products CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing Services
  • 9.3. Process Development Services
  • 9.4. Regulatory & Compliance Support

10. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Hematology
  • 10.4. Neurology
  • 10.5. Oncology

11. Advanced Therapy Medicinal Products CDMO Market, by Application

  • 11.1. Clinical Stage
  • 11.2. Commercial Stage

12. Advanced Therapy Medicinal Products CDMO Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies

13. Advanced Therapy Medicinal Products CDMO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Therapy Medicinal Products CDMO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Therapy Medicinal Products CDMO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abzena
    • 16.3.2. Advanced Therapies, LLC
    • 16.3.3. AGC Inc.
    • 16.3.4. Aldevron
    • 16.3.5. Almac Group
    • 16.3.6. Bio Elpida by Polyplus
    • 16.3.7. BlueReg
    • 16.3.8. Catalent Inc.
    • 16.3.9. CELONIC Group
    • 16.3.10. CGT Catapult
    • 16.3.11. Charles River Laboratories International, Inc.
    • 16.3.12. Coriolis Pharma Research GmbH
    • 16.3.13. Curia Global, Inc.
    • 16.3.14. Eurofins Scientific SE
    • 16.3.15. FUJIFILM Diosynth Biotechnologies
    • 16.3.16. Lonza Group
    • 16.3.17. Minaris Regenerative Medicine
    • 16.3.18. Oxford Biomedica PLC
    • 16.3.19. Patheon by Thermo Fisher Scientific Inc.
    • 16.3.20. Recipharm AB
    • 16.3.21. Rentschler Biopharma SE
    • 16.3.22. REPROCELL Inc.
    • 16.3.23. RoslinCT
    • 16.3.24. Samsung Biologics
    • 16.3.25. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ADVANCED THERAPY MEDICIN